鲁米诺科克斯菌通过拉酶驱动的耐性粉降解和微生物群调节来缓解便秘.
Rong Li1, Qianqian Yang1, Junqing He1
1Key Laboratory of Molecular Biophysics of the Ministry of Education, Hubei Key Laboratory of Bioinformatics and Molecular Imaging, Department of Biotechnology, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
NPJ biofilms and microbiomes
|December 13, 2025
概括
鲁米诺菌通过降解耐性粉,促进有益的肠道细菌和短链脂肪酸来缓解便秘. 这一发现突出了R. bromii作为便秘治疗的潜在目标.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 代谢途径 代谢途径
背景情况:
- 便秘是一种常见的胃肠道问题,与肠道微生物群的变化有关.
- 便秘的特定微生物点和机制尚不清楚.
- 发现Ruminococcus属在便秘个体中已经耗尽.
研究的目的:
- 为了研究鲁米诺菌物种在便秘中的作用.
- 为了确定导致便秘的微生物机制.缓解便秘.
- 评估R. bromii作为一种潜在的治疗便秘的药物.
主要方法:
- 在便秘患者的肠道微生物组合的分析.
- 在小鼠便秘模型中测试四种鲁米诺菌 (R. bromii,R. torques,R. obeum,R. gnavus).
- 研究R. bromii的酶活性,特别是它的pullulanase.
- 评估耐性粉降解对肠道微生物群和短链脂肪酸生产的影响.
- 进行临床试验以验证在人类中的发现.
主要成果:
- 所有测试的Ruminococcus物种都减轻了小鼠的便秘症状.
- R. bromii 显示出最显著的疗效.
- R. bromii 的 pullulanase 酶降解了耐性粉,增加了短链脂肪酸.
- 耐性粉的摄入促进了有益的细菌,如阿克尔曼西亚和Bifidobacterium.
- 临床试验证实,抗性粉在缓解便秘方面的有效性取决于R. bromii的丰富性.
结论:
- R. bromii被认为是缓解便秘的关键微生物媒介.
- 该机制涉及耐性粉代谢,导致有益的微生物转移.
- R. bromii 是新型益生菌或共生菌便秘治疗的有希望的候选者.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
676
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
676
Drugs for Treatment of Diarrhea-Predominant IBS
598
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
598
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
508
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
508
Drugs Affecting GI Tract Motility: Other Laxatives
983
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
983
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
549
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
549
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
855
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
855


